#ACR2022 L07: Telitacicept - anti-BlyS and APRIL in SLE 335 pts P3 52 wk study TEL 160 mg SQ q7d vs PBO 83% SRI4 response in TEL vs 38% PBO (p<0.001) As early as w4, sustained to w52 Most common AEs: URIs, decr IgG/IgM, injxn site rxn, UTI @RheumNow #ACRBest https://t.co/UpEwEaonDO

Khanna et al Transdermal NaHCO₃ in gout flare. N=98. Response rate D7 95% vs 79% (p=0.01). Lower rescue med, 6% vs 20%. @RheumNow #ACR22 Abstr#1787 https://t.co/DWtlvjzBHw https://t.co/DOk993gCwz

Joy et al. Disease activity rather than steroid use increases risk of diabetes in RA in BeST study over 10 years. @RheumNow #ACR22 Abstr#1987 https://t.co/VT2eb3Q4m9 https://t.co/kquZ70o9bU

L08 #ACR22 TIX/CIL (Evusheld) in Rheum Pts 157 pts, f/u 154 days 24 breakthrough COVID ifns (15%) 2 pts required hospitalization, rest had mild-mod symptoms No SAEs (CVD) @RheumNow

#ACR22 Best in PsA and SpA - new Rxs, unraveling responses to Rx by sex/gender. X-ray inhibition w SpA drugs is a reality. Nice peeps working in these areas @RheumNow @ACRheum https://t.co/8VfdyyHPZi

Here's the 1 year model #ACR22 @RheumNow https://t.co/VhEuJMMyIt

Eder et al. New PRESTO prediction model for PsA development in PsO. 1 year and 5 year models presented @RheumNow #ACR22 Abstr#1612 https://t.co/xMMVaIGnN5 https://t.co/RlJ3ZlEeDE

Krijbolder et al. TREAT EARLIER DBRCT. MTX vs PBO for pre-RA. Treat 1 year, stop, and follow 1 year. No difference in RA development. Delay in ACPA+ or high risk. Sustained benefit in MTX group on pain, EMS, function, MRI. @RheumNow #ACR22 Abstr#1603 https://t.co/M2qQfgrhC1 https://t.co/UUeknTLx0K

Yazici et al. RCT of IA Lorecivivint for moderate/severe knee OA. CLK/DYRK inhibitor. No effect seen. @RheumNow #ACR22 Abstr#1899 https://t.co/XGQrMmNnSR https://t.co/rSJrT6Hms6

Bihlet et al. Anti-histamines may reduce structural progression of knee OA. Post-hoc analysis of 2 trials @RheumNow #ACR22 Abstr#1893 https://t.co/RrrelHDz75 https://t.co/Sf7RpjjAaN